News | October 29, 2007

NIH Awards Penn $2.1M for Cardiovascular Disease Management Study

October 30, 2007 – The National Institutes of Health (NIH) has awarded cardiac researchers at the University of Pennsylvania a $2.1 million grant to pioneer studies in cardiovascular disease management and participate in a novel collaboration network to develop and implement research in this critically important field.
Penn is one of eight centers throughout the United States and Canada to be a named a Clinical Coordinating Center in the National Heart Lung and Blood Institute (NHLBI)-funded Clinical Research Network. This network will fund the creation of research and clinical trials that will answer questions in cardiothoracic surgery that have eluded researchers thus far.

The eight institutions that comprise the Cardiothoracic Surgical Network will collaborate over a five-year period to improve current technologies and create new ones to treat cardiovascular disease. “The establishment of this network will result in great benefit for patients. It also encourages leaders in cardiovascular surgery to share ideas, information, data and results,” said Michael Acker, M.D., chief of Cardiovascular Surgery at the Hospital of the University of Pennsylvania, and principal investigator for the grant.

“By enhancing the ability of research teams to evaluate new techniques, technologies and devices, the network promises to improve the scientific basis of care in cardiovascular disease,” said Elizabeth G. Nabel, M.D., director of the National Heart, Lung and Blood Institute of the National Institutes of Health.

The Penn researchers will propose protocols and participate in protocol development; screen and recruit cardiac surgery for up to five randomized clinical studies in cardiac surgery; develop strategies to encourage referrals from other specialty areas; draft publications and distribute research findings; and collaborate with other centers.

The seven other heart centers participating in this landmark NIH study are: the Cleveland Clinic, Columbia University, Duke Medical Center, Emory University, Montefiore-Einstein Heart Center, University of Virginia and the Montreal Heart Institute.

For more information: www.med.upenn.edu


Related Content

News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 18, 2025 — (Newswise) It’s often mistaken for a heart attack, but Takotsubo cardiomyopathy — previously known as ...

Home August 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 20, 2025 — A major international study published in Atherosclerosis* has found that routinely testing for ...

Home August 20, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 4, 2025 — Marea Therapeutics, Inc., a clinical-stage biotechnology company that develops next-generation medicines ...

Home August 04, 2025
Home
News | Cardiovascular Clinical Studies

July 16, 2025 — Medtronic has announced that the first patient has been enrolled in the PEripheral Onyx Liquid Embolic ...

Home July 22, 2025
Home
News | Cardiovascular Clinical Studies

June 11, 2025 — Bayer and the Broad Institute have have extended their research collaboration of 10 years by an ...

Home June 11, 2025
Home
News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
Subscribe Now